Product Description
Mechanisms of Action: D2 Blocker
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Ireland | New Zealand
Approved Indications: None
Known Adverse Events: None
Company: Canadian Network for Observational Drug Effect Studies, CNODES
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| Q10-12 | N/A |
Completed |
Affective Disorders, Psychotic|Schizophrenia|Type 2 Diabetes|Psychotic Disorders|Bipolar Disorder |
2012-12-01 |
2024-10-16 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|